This study was designed to investigate the modulatory effect of dietary soybean protein on the skeleton of an ovariectomized rat model with postmenopausal osteoporosis. Thirty-two female Sprague-Dawley rats were weight matched and divided into the following four experimental groups: Soy group, ovariectomized and fed soy protein diet; Estrogen group, ovariectomized, fed casein diet and injected with estrogen; Casein group, ovariectomized and fed casein diet; and Sham group, sham-operated and fed casein diet. The diets and estrogen were started two weeks after surgery, and continued for four weeks. Rats in the Sham, Soy and Estrogen groups had significantly higher (p<0.05) femur and tibia ash content than those in the Casein group. Accordingly, the calcium content of the tibia and femur were also significantly higher (p<0.05) in the Soy, Estrogen and Sham groups as compared to the Casein group. Serum total and bone-type alkaline phosphatase levels were both significantly lower (p<0.05) in the Estrogen and Sham groups in relation to the Soy and Casein groups. This study demonstrated that a 22% soybean protein diet could be just as effective as daily estrogen administration in suppressing bone loss due to ovariectomy. However, unlike estrogen, soy protein diet did not have any uterotrophic effect and did not decrease the markers of bone turnover measured, suggesting a possible difference in the mechanism of action. Key Words soy protein, ovariectomy, estrogen, bone loss osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in an increase in bone fragility and susceptibility to fractures (1).
the femoral neck, vertebra and lower forearm (2). Development of osteoporosis depends on peak bone mass achieved, rate of bone loss, maintenance of bone microarchitecture and duration of life. These are related to a composite mixture and inter-relationships of genetics, lifestyles, reproductive history, disease and its treatment, body weight and composition, and diet throughout life (3). Postmeno pausal osteoporosis (PMO), resulting from the loss of estrogen at menopause, is associated with a rapid reduction of bone mass, leading to porotic bones prone to fractures.
Estrogen replacement can effectively prevent this rapid bone loss in postmeno pausal women (4) and clinically relevant animal models (5), establishing a protec tive effect of estrogen on the skeleton. It is now well established that Estrogen Replacement Therapy (ERT) increases bone mineral density and decreases the risk of future bone fracture (6). To prevent postmenopausal bone loss, it is recommended that ERT be initiated soon after menopause and continued indefinitely (6), making estrogen replacement the cornerstone of preventive therapy for osteoporotic fractures. Existing data suggest that the beneficial skeletal effect of ERT can be maintained only as long as administration of the hormone is continued and that cessation of the therapy may result in a rapid loss of bone tissue to the level seen in untreated subjects (7). In addition, although the beneficial effects are clear, the overall value of ERT has been questioned due to estrogen-related side effects, many of which are related to hormonal stimulation of the reproductive tissues (8), including uterine stimulation and increased risk of endometrial cancer (9). As a result of these potential long-term risks of estrogen replacement, there is the need for alternative therapeutic measures that may be relatively risk free and equally beneficial. Compounds in the diet that have properties similar to, or are antagonists of the physiologic estrogens may play a role in reducing the risk and/or extent of osteoporosis. Soybean is a rich source of phytoestrogens, which are non-steroidal estrogens of the isoflavone class (10). These compounds are structurally similar to the mammalian estrogen, estradiol. The principal compounds within these classes of phytoestrogens have been shown to have weak estrogenic activity, possess affinity for estrogen receptors and produce typical and predictable estrogenic responses when administered to animals, behaving as partial estrogen agonists and antagonists depending on the presence or absence of estrogens (11, 12). A few reports have indicated some beneficial effect of soybean diets on the skeleton of ovariectomized rats (13, 14) . The ovariectomized rat model is suitable for studying problems that are relevant to postmenopausal bone loss (15) and has proven to be useful for investigating the cellular mechanisms of estrogen action on the skeleton (5, 16). Consequently, this study was designed to investigate the modulatory effect of dietary soybean protein on the skeleton of an ovariectomized rat model with PMO. 
MATERIALS AND METHODS

Animals
RESULTS
Body weight and food intake Rats in all four experimental groups had similar initial body weights. At the end of the experiment, however, the estrogen-treated rats had a significantly lower body weight (p<0.05) than the Casein and Soy groups but not the sham-operated controls ( Table 2 ). The mean daily food intake of all the animal was 14.2g, since they were pair-fed. The differences in the final body weights of the groups were therefore not due to differences in amount of food ingested.
Organ weights
The weights of the spleen, kidneys, uterus, liver and adrenal glands of the groups are presented in Table 2 . Ovariectomy resulted in the atrophy of the uterus which was reversed by estrogen treatment. The uterine weight of rats in the Casein and Soy groups remained significantly smaller (p<0.05). The weight of both the spleen and kidneys showed no significant differences among the four experimental groups. Ovariectomy caused a significant decrease (p<0.05) in the weight of the adrenal glands, which could not be reversed by estrogen treatment. Compared to the sham-operated controls, the Soy group had significantly smaller liver weights (p<0.05). The Casein group also tended to have smaller liver weights compared to the Sham group, but the differences were not significant. Estrogen administration, however, resulted in a significant increase (p<0.05) in liver weight.
Femur and tibia weight The wet and dry weights of both the femur and tibia of the experimental groups are shown in Table 3 . Compared to the Sham group, ovariectomy caused a slight decrease in the wet weight of the tibia in the Casein group, which was prevented by the soy diet and estrogen treatment. Similar trends were observed in the dry weight of both the femur and tibia. The decrease in the wet weight of the femur was small after ovariectomy, but the feeding of soy protein diet resulted in a significant increase (p<0.05), whereas the increase after estrogen administration tended to be high.
Ash content of tibia and femur The ash weight of both the tibia and femur showed similar trends (Fig. 1) . Compared to the sham-operated controls, the ash weights in the Soy and Estrogen groups were not different. The rats in the Casein group, however, had significantly smaller tibia and femur ash weights (p<0.05).
Calcium content of tibia and femur
The calcium contents of the femur in the Sham, Soy and Estrogen groups were not different from each other, but they were all significantly higher (p<0.05) than that in the Casein group (Fig. 2) . Compared to the Sham group, the calcium contents of the tibia in the Soy and Estrogen groups were significantly higher (p<0.05), while that of the Casein group was significantly lower (p<0.05), as shown in Fig. 2 . Table 4 shows the serum calcium, phosphorus, T-Alp and B-Alp levels in the Vol 44, No 2, 1998 four experimental groups. While there were no sigificant differences among the serum calcium and phosphorus levels, the T-Alp and B-Alp levels in the Sham and Estrogen groups were both significantly lower (p<0.05) than those in the Casein and Soy groups. The B-ALP level in the Sham group was however , significantly higher (p<0.05) than that in the Estrogen group.
Serum assay
DISCUSSION
This study has shown the effects of estrogen treatment and soybean protein diet on ovariectomized rats. The effects of ovariectomy on rat bone, organ weights and serum biochemical indices observed in this study have also been variously reported by other investigators (14, 17, 18). The beneficial effects of estrogen treatment are well documented by many researchers for both ovariectomized rats (5, 19, 20) and postmenopausal women (6, 21, 22). These and other similar findings form the basis for ERT. The positive effects of soybean diet on the skeleton of ovariectomized rats have also been reported by two other investigators (13, 14), where bone mineral density and bone strength were increased.
Postmenopausal bone loss is associated with a high bone turnover; both the resorption and formation of bone are increased, but resorption is relatively greater and the outcome is a net loss of bone. The accelerated loss is a result of declining ovarian function (23). This is similar in the ovariectomized rat because ovariectomy also causes a progressive loss of bone matrix. The characteristics of ovariectomy include high bone-turnover ratio with resorption exceeding formation; an initial rapid phase of bone resorption followed by a slower phase, and a significant loss of cancellous bone rather than cortical bone (15). In this study, bone loss was seen in the slight decrease in the dry and wet weights of the tibia and femur, together with the significant decrease in their ash and calcium contents, and the rise in the serum levels of both T-Alp and B-Alp, markers of bone turnover.
The precise mechanism of action of estrogen in the treatment of PMO has not Equol possesses weak estrogenic activity , in the order of 10-3 times that of estradiol (38) , while that of genistein is about 10-3 to 10-5 that of estradiol (39) . Phytoestrogens have also been reported to produce uterotrophic effects in animals (40) , but this was not observed in our study or that of other researchers (14). This lack of uterotrophic activity could, however , be beneficial in reducing the risk of endometrial cancer associated with ERT. The effects of soy isoflavones also differed from that of estrogen with regard to the markers of bone turnover (serum T-Alp and B-Alp) measured in this experiment. Although there was a significant decrease with estrogen treatment, there was no response after a diet of soy protein . A similar result was obtained by Arjmandi et al (14) . This suggests that the mechanism of action of estradiol and isoflavones in soybeans may differ in relation to their skeletal effects. The difference between our study and that of Arjmandi et al is in the dosage of estradiol given and the period between surgery and commencement of treatment .
We injected a higher dose and started treatment two weeks after surgery (to allow for the development of moderate osteopenia) , while they started treatment from the day of surgery. The results obtained are similar however , suggesting that soy protein diet may not only be effective in the prevention but also in the treatment of estrogen-deficiency bone loss. Bone histomorphometric studies are needed to address and confirm this observation. Apart from isoflavones , other components of soybean, like peptides, have also been implicated in increasing the bone mineral density and bone strength of ovariectomised rats by other researchers (13) . The authors suggested that the skeletal effects were possibly due to the acceleration of intestinal calcium absorption by the peptides in soybean . They, however, concluded that further studies are required to identify which peptides or amino acid sequences are involved and precisely how bone metabolism is affected .
In conclusion, this study has demonstrated that a soybean protein diet could be just as effective as daily estradiol administration in suppressing bone loss due to ovariectomy, and that the results provide support for soy diet as a potentially effective alternative to ERT for the maintenance of postmenopausal bone mass and protection against and treatment of PMO. 
